323 results match your criteria: "Centre Hospitalier Universitaire de Tours.[Affiliation]"
J Prev Alzheimers Dis
January 2025
Geriatrics Department, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France; Paris-Cité University, Inserm U1144, Paris, France; Paris-Cité University, Inserm U1153, Paris, France.
Background: The use of cerebrospinal (CSF) biomarkers in the diagnosis of Alzheimer's disease (AD) has been gaining interest in clinical practice. Although their usefulness has been demonstrated, their potential value in older patients remains debated.
Objectives: To assess whether knowledge of the results of CSF AD biomarkers was associated with the same gain in diagnostic confidence in older adults > 80 than in younger patients.
JMIR Res Protoc
January 2025
INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.
Background: : With more than 60 million new cases around the world each year, traumatic brain injury (TBI) causes substantial mortality and morbidity. Managing TBI is a major human, social, and economic concern. In the last 20 years, there has been an increase in clinical trials in neurocritical care, leading mostly to negative results.
View Article and Find Full Text PDFNeuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFBJOG
December 2024
Gynécologie-Obstétrique, Faculté de Médecine, Clinique Des Universités, Tours, France.
Objective: We aim to clarify potential risk factors of complications after uterine artery embolisation (UAE).
Setting: Complications after uterine artery embolisation (UAE) for symptomatic fibroids are rare, but failure of treatment occurs for approximately 13%-24% of patients at 10 years.
Design: We conducted a case-control study including all complications post UAE over 15 years in our specialised unit.
Virchows Arch
November 2024
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France.
Recurrent mutations in the CTNNB1 or APC genes leading to the activation of the Wnt/betacatenin pathway are observed in adnexal tumors with matrical differentiation. While most pilomatricomas arise sporadically and harbor CTNNB1 mutations, cutaneous hybrid cysts combining epidermal and matrical differentiations have been mostly reported in a context of the familial adenomatosis polyposis/Gardner's syndrome related to germinal mutations of APC. The objective of this study is to understand the pathogenesis of hybrid cysts combining epidermal and matrical differentiations.
View Article and Find Full Text PDFHistopathology
November 2024
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France.
Aims: Sebaceous neoplasms constitute a group of adnexal tumours, including sebaceous adenoma, sebaceoma and sebaceous carcinoma. Although mismatch repair deficiency may be observed, the nature of the genetic alterations contributing to the development of most of these tumours is still unknown. In the present study, we describe the clinical, microscopic, and molecular features of eight sebaceomas with GRHL gene rearrangement.
View Article and Find Full Text PDFPathology
February 2025
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; CARADERM Network, France; 'Biologie des infections à polyomavirus' Team, UMR INRA ISP 1282, Université de Tours, Tours, France.
Front Microbiol
September 2024
Service de Bactériologie-Virologie-Hygiène, Centre Hospitalier Universitaire de Tours, Tours, France.
Open Forum Infect Dis
September 2024
Department of Nephrology, Transplantation, Dialysis and Apheresis, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Virchows Arch
October 2024
CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.
Circulation
November 2024
ACTION Study Group, INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne Université (P.G., M.L., T.R., Y.T., M.E.G., D.B., J.S., N.H., G.D., G.M.), Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.
Background: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure.
Methods: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design).
Ann Dermatol Venereol
September 2024
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, 37044 Tours, France. Electronic address:
Cancer Radiother
December 2024
Service de radiothérapie, centre régional de cancérologie Henry-S.-Kaplan, centre hospitalier universitaire de Tours, 2, boulevard Tonnellé, Tours, France.
Purpose: This retrospective study was conducted to ensure that irradiation of the pelvic lymph node areas associated with simultaneous hypofractionated boost to the prostate according to the protocol implemented at the university hospital of Tours (France) does not result in excess urinary and digestive toxicity in the short and medium term.
Materials And Methods: The study population included patients with localized unfavourable intermediate or high-risk prostate cancer. The dose delivered was 65Gy in 25 fractions of 2.
Resuscitation
October 2024
Service des Urgences, Centre Hospitalier Universitaire de Nantes, F-44000 Nantes, France.
Introduction: Early assessment of the prognosis of a patient in cardiac arrest during cardiopulmonary resuscitation is highly challenging. This study aims to evaluate the predictive outcome value of early point-of-care ultrasound (POCUS) in out-of-hospital settings.
Methods: This observational, prospective, multicentre study's primary endpoint was the positive predictive value (PPV) of POCUS cardiac standstill within the first 12 min of advanced life support (ALS) initiation in determining the absence of return of spontaneous circulation (ROSC).
Pathology
December 2024
Department of Biopathology, Center Léon Bérard, Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France.
Mod Pathol
November 2024
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; "Biologie des infections à polyomavirus" Team, UMR INRA ISP 1282, Université de Tours, Tours, France.
Trends Mol Med
December 2024
Centre de Référence sur la SLA de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; UMR 1253, iBRAIN, Université de Tours, INSERM, Tours, France.
The identification of biomarkers for amyotrophic lateral sclerosis (ALS) is a central issue in disease research. In a recent article, Chatterjee et al. show that blood extracellular vesicles (EVs) with high levels of transactive response DNA-binding protein 43 (TDP-43) accurately discriminate patients with ALS from controls and correlate with disease severity, providing a promising biomarker for early diagnosis and monitoring.
View Article and Find Full Text PDFJ Pathol
September 2024
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
J Cutan Pathol
October 2024
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Chambray-les-tours, France.
Context: Merkel cell carcinoma diagnosis is often based on microscopic examination by pathologists. While histopathologic diagnosis primarily hinges on conscious and analytical cognition, the pathologist's decision-making process is also influenced by a rapid "gist" or "gestalt" approach. In this study, using cases of Merkel cell carcinoma as a model, we aim to assess how pathologists' viewing short videos containing conceptual clues and visual aids, in conjunction with reading an original article as a reference, may enhance their diagnostic performance.
View Article and Find Full Text PDFCrit Care
July 2024
Laboratoire de Psychologie: Dynamiques Relationnelles Et Processus Identitaires (Psy-DREPI), Université de Bourgogne Franche-Comté, EA7458, Dijon, France.
Background: Critical-illness survivors may experience post-traumatic stress disorder (PTSD) and quality-of-life impairments. Resilience may protect against psychological trauma but has not been adequately studied after critical illness. We assessed resilience and its associations with PTSD and quality of life, and also identified factors associated with greater resilience.
View Article and Find Full Text PDFMerkel cell carcinoma (MCC) is a highly aggressive skin cancer associated with integration of Merkel cell polyomavirus (MCPyV). MCPyV-encoded T-antigens (TAs) are pivotal for sustaining MCC's oncogenic phenotype, i.e.
View Article and Find Full Text PDFESMO Open
July 2024
Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon.
Background: Nivolumab is the first immune checkpoint inhibitor approved in Europe for the treatment of advanced renal cell carcinoma (aRCC) in patients resistant to prior antiangiogenic therapy. WITNESS is an ongoing, prospective, observational study designed to evaluate the effectiveness and safety of nivolumab in patients with aRCC treated in real life (or routine practice) in France (ClinicalTrials.gov identifier: NCT03455452).
View Article and Find Full Text PDFPathology
October 2024
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; "Biologie des Infections à Polyomavirus" Team, UMR INRA ISP 1282, Université de Tours, Tours, France; CARADERM Network, France. Electronic address:
Virchows Arch
October 2024
Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France.